MicroRNAs in nonalcoholic fatty liver disease: Novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Gori, Manuele ^a   Arciello, Mario ^a,b   Balsano, Clara ^a  

^a Laboratory of Molecular Virology and Oncology Francesco Balsano Foundation   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; MICRORNA; MICRORNA 10B; MICRORNA 122; MICRORNA 141; MICRORNA 155; MICRORNA 16; MICRORNA 181A; MICRORNA 181B; MICRORNA 199A; MICRORNA 199B; MICRORNA 199B 3P; MICRORNA 200; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 21; MICRORNA 221; MICRORNA 33A; MICRORNA 33B; MICRORNA 34A; MICRORNA 99A; MICRORNA 99B; MICRORNA LET 7; UNCLASSIFIED DRUG; RNA;

BIOGENESIS; CARCINOGENESIS; DISEASE COURSE; DISEASE SEVERITY; HUMAN; IN VITRO STUDY; LINEAR ENERGY TRANSFER; LIPID LIVER LEVEL; LIPID METABOLISM; LIVER CELL; LIVER CELL CARCINOMA; LIVER EXAMINATION; NONALCOHOLIC FATTY LIVER; REVIEW; SCREENING; STEATOSIS; ANIMAL; BIOSYNTHESIS; GENE EXPRESSION REGULATION; LIVER TUMOR; METABOLISM; PATHOLOGY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MICRORNAS; NON-ALCOHOLIC FATTY LIVER DISEASE; RNA, NEOPLASM;

EID: 84897505627     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/741465     Document Type: Review

References (127)

1. Starley B. Q., Calcagno C. J., Harrison S. A., Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010 51 5 1820 1832 2-s2.0-77951456114 10.1002/hep.23594
2. Marra F., Gastaldelli A., Svegliati Baroni G., Tell G., Tiribelli C., Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends in Molecular Medicine 2008 14 2 72 81 2-s2.0-39149104311 10.1016/j.molmed.2007.12.003
3. Sakamoto M., Effendi K., Masugi Y., Molecular diagnosis of multistage hepatocarcinogenesis. Japanese Journal of Clinical Oncology 2010 40 9 891 896 2-s2.0-77956110536 10.1093/jjco/hyq099 hyq099
4. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., Natale S., Vanni E., Villanova N., Melchionda N., Rizzetto M., Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003 37 4 917 923 2-s2.0-0037382786 10.1053/jhep.2003.50161 (Pubitemid 36397405)
5. Schaffner F., Thaler H., Nonalcoholic fatty liver disease. Progress in Liver Diseases 1986 8 283 298 2-s2.0-0022568321
6. Rorat M., Jurek T., Kuchar E., Szenborn L., Golema W., Halon A., Liver steatosis in Polish children assessed by medicolegal autopsies. World Journal of Pediatrics 2013 9 1 68 72 10.1007/s12519-012-0387-8
7. Veteläinen R., van Vliet A., Gouma D. J., van Gulik T. M., Steatosis as a risk factor in liver surgery. Annals of Surgery 2007 245 1 20 30 2-s2.0-33845922813 10.1097/01.sla.0000225113.88433.cf (Pubitemid 46035431)
8. Ong J. P., Younossi Z. M., Epidemiology and natural history of NAFLD and NASH. Clinics in Liver Disease 2007 11 1 1 16 2-s2.0-34249668818 10.1016/j.cld.2007.02.009 (Pubitemid 46829973)
9. Bhala N., Jouness R. I., Bugianesi E., Epidemiology and natural history of patients with NAFLD. Current Pharmaceutical Design 2013 19 29 5169 5176 10.2174/13816128113199990336
10. Hashimoto E., Yatsuji S., Tobari M., Taniai M., Torii N., Tokushige K., Shiratori K., Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Journal of Gastroenterology 2009 44 19, supplement 89 95 2-s2.0-58849090967 10.1007/s00535-008-2262-x
11. Rahman R., Hammoud G. M., Almashhrawi A. A., Ahmed K. T., Ibdah J. A., Primary hepatocellular carcinoma and metabolic syndrome: an update. World Journal of Gastrointestinal Oncology 2013 5 9 186 194 10.4251/wjgo.v5.i9.186
12. Brunt E. M., Nonalcoholic fatty liver disease: what the pathologist can tell the clinician. Digestive Diseases 2012 30 supplement 1 61 68 10.1159/000341127
13. Westin J., Lagging L. M., Wejstål R., Norkrans G., Dhillon A. P., Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. Liver 1999 19 3 183 187 2-s2.0-0032979608 10.1111/j.1478-3231.1999.tb00033.x (Pubitemid 29261583)
14. Bedossa P., Dargère D., Paradis V., Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003 38 6 1449 1457 2-s2.0-0345017740 10.1016/j.hep.2003.09.022 (Pubitemid 37466971)
15. Nugent C., Younossi Z. M., Evaluation and management of obesity-related nonalcoholic fatty liver disease. Nature Clinical Practice Gastroenterology & Hepatology 2007 4 8 432 441 2-s2.0-34547683485 10.1038/ncpgasthep0879 (Pubitemid 47208893)
16. Tandon P., Garcia-Tsao G., Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver International 2009 29 4 502 510 2-s2.0-62749123476 10.1111/j.1478-3231.2008.01957.x
17. Mendy M., Walton R., Molecular pathogenesis and early detection of hepatocellular carcinoma-perspectives from West Africa. Cancer Letters 2009 286 1 44 51 2-s2.0-70350767515 10.1016/j.canlet.2009.04.039
18. Bertino G., Ardiri A., Malguarnera M., Malaguarnera G., Bertino N., Calvagno G. S., Hepatocellular carcinoma serum markers. Seminars in Oncology 2012 39 4 410 433 10.1053/j.seminoncol.2012.05.001
19. Singhal A., Jayaraman M., Dhanasekaran D. N., Kohli V., Molecular and serum markers in hepatocellular carcinoma: predictive tools for prognosis and recurrence. Critical Reviews in Oncology/Hematology 2012 82 2 116 140 2-s2.0-84859433790 10.1016/j.critrevonc.2011.05.005
20. Liu H., Li P., Zhai Y., Qu C.-F., Zhang L.-J., Tan Y.-F., Li N., Ding H.-G., Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World Journal of Gastroenterology 2010 16 35 4410 4415 2-s2.0-77957558765 10.3748/wjg.v16.i35.4410
21. Nagoshi S., Osteopontin: versatile modulator of liver diseases. Hepatology Research 2013 44 1 22 30 10.1111/hepr.12166
22. Lydatakis H., Hager I. P., Kostadelou E., Mpousmpoulas S., Pappas S., Diamantis I., Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease. Liver International 2006 26 7 864 871 2-s2.0-33746732177 10.1111/j.1478-3231.2006.01312.x (Pubitemid 44165255)
23. Sayed D., Abdellatif M., MicroRNAs in development and disease. Physiological Reviews 2011 91 3 827 887 2-s2.0-79960104144 10.1152/physrev. 00006.2010
24. Bartel D. P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004 116 2 281 297 2-s2.0-0347444723 10.1016/S0092-8674(04)00045-5 (Pubitemid 38167318)
25. Chang T.-C., Mendell J. T., MicroRNAs in vertebrate physiology and human disease. Annual Review of Genomics and Human Genetics 2007 8 215 239 2-s2.0-35348821616 10.1146/annurev.genom.8.080706.092351
26. Olena A. F., Patton J. G., Genomic organization of microRNAs. Journal of Cellular Physiology 2010 222 3 540 545 2-s2.0-73649110251 10.1002/jcp.21993
27. Rodriguez A., Griffiths-Jones S., Ashurst J. L., Bradley A., Identification of mammalian microRNA host genes and transcription units. Genome Research 2004 14 10 1902 1910 2-s2.0-6344281172 10.1101/gr.2722704 (Pubitemid 39386503)
28. Qu H., Xu W., Huang Y., Yang S., Circulating miRNAs: promising biomarkers of human cancer. Asian Pacific Journal of Cancer Prevention 2011 12 5 1117 1125 2-s2.0-84856288684
29. Zen K., Zhang C.-Y., Circulating MicroRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Medicinal Research Reviews 2012 32 2 326 348 2-s2.0-84857666519 10.1002/med.20215
30. Bala S., Marcos M., Szabo G., Emerging role of microRNAs in liver diseases. World Journal of Gastroenterology 2009 15 45 5633 5640 2-s2.0-74049085924 10.3748/wjg.15.5633
31. Cermelli S., Ruggieri A., Marrero J. A., Ioannou G. N., Beretta L., Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS ONE 2011 6 8 2-s2.0-80052008851 10.1371/journal.pone. 0023937 e23937
32. Murakami Y., Yasuda T., Saigo K., Urashima T., Toyoda H., Okanoue T., Shimotohno K., Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006 25 17 2537 2545 2-s2.0-33646157967 10.1038/sj.onc.1209283
33. Meng F., Henson R., Wehbe-Janek H., Ghoshal K., Jacob S. T., Patel T., MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007 133 2 647 658 2-s2.0-34547524771 10.1053/j.gastro.2007.05.022 (Pubitemid 47187346)
34. Boominathan L., The tumor suppressors p53, p63, and p73 are regulators of microRNA processing complex. PLoS ONE 2010 5 5 2-s2.0-77956279586 10.1371/journal.pone.0010615 e10615
35. Cheung O., Puri P., Eicken C., Contos M. J., Mirshahi F., Maher J. W., Kellum J. M., Min H., Luketic V. A., Sanyal A. J., Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 2008 48 6 1810 1820 2-s2.0-58149386462 10.1002/hep.22569
36. Li S., Chen X., Zhang H., Liang X., Xiang Y., Yu C., Zen K., Li Y., Zhang C.-Y., Differential expression of microRNAs in mouse liver under aberrant energy metabolic status. Journal of Lipid Research 2009 50 9 1756 1765 2-s2.0-70349393847 10.1194/jlr.M800509-JLR200
37. Jin X., Ye Y.-F., Chen S.-H., Yu C.-H., Liu J., Li Y.-M., MicroRNA expression pattern in different stages of nonalcoholic fatty liver disease. Digestive and Liver Disease 2009 41 4 289 297 2-s2.0-62049083189 10.1016/j.dld.2008.08.008
38. Fernández-Hernando C., Suárez Y., Rayner K. J., Moore K. J., MicroRNAs in lipid metabolism. Current Opinion in Lipidology 2011 22 2 86 92 2-s2.0-79953740452 10.1097/MOL.0b013e3283428d9d
39. Estep M., Armistead D., Hossain N., Elarainy H., Goodman Z., Baranova A., Chandhoke V., Younossi Z. M., Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics 2010 32 3 487 497 2-s2.0-77954342986 10.1111/j.1365-2036.2010.04366.x
40. Sharma H., Estep M., Birerdinc A., Expression of genes for miRNAs processing enzymes is altered in advanced non alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 2013 28 8 1410 1415 10.1111/jgh.12268
41. Moore K. J., Rayner K. J., Suárez Y., Fernández-Hernando C., The role of MicroRNAs in cholesterol efflux and hepatic lipid metabolism. Annual Review of Nutrition 2011 31 49 63 2-s2.0-79960523356 10.1146/annurev- nutr-081810-160756
42. Sacco J., Adeli K., MicroRNAs: emerging roles in lipid and lipoprotein metabolism. Current Opinion in Lipidology 2012 23 3 220 225 2-s2.0-84859395368 10.1097/MOL.0b013e3283534c9f
43. Iliopoulos D., Drosatos K., Hiyama Y., Goldberg I. J., Zannis V. I., MicroRNA-370 controls the expression of MicroRNA-122 and Cpt1 α and affects lipid metabolism. Journal of Lipid Research 2010 51 6 1513 1523 2-s2.0-77952707662 10.1194/jlr.M004812
44. Elmén J., Lindow M., Schütz S., Lawrence M., Petri A., Obad S., Lindholm M., Hedtjärn M., Hansen H. F., Berger U., Gullans S., Kearney P., Sarnow P., Straarup E. M., Kauppinen S., LNA-mediated microRNA silencing in non-human primates. Nature 2008 452 7189 896 899 2-s2.0-42249093319 10.1038/nature06783 (Pubitemid 351550859)
45. Tryndyak V. P., Latendresse J. R., Montgomery B., Ross S. A., Beland F. A., Rusyn I., Pogribny I. P., Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline- and folate-deficient diet. Toxicology and Applied Pharmacology 2012 262 1 52 59 10.1016/j.taap.2012.04.018
46. Yamada H., Suzuki K., Ichino N., Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clinica Chimica Acta 2013 424 99 103 10.1016/j.cca.2013.05.021
47. Kutay H., Bai S., Datta J., Motiwala T., Pogribny I., Frankel W., Jacob S. T., Ghoshal K., Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. Journal of Cellular Biochemistry 2006 99 3 671 678 2-s2.0-33749479908 10.1002/jcb.20982 (Pubitemid 44521987)
48. Gramantieri L., Ferracin M., Fornari F., Veronese A., Sabbioni S., Liu C.-G., Calin G. A., Giovannini C., Ferrazzi E., Grazi G. L., Croce C. M., Bolondi L., Negrini M., Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Research 2007 67 13 6092 6099 2-s2.0-34447117003 10.1158/0008-5472.CAN-06-4607 (Pubitemid 47037488)
49. Kojima K., Takata A., Vadnais C., Otsuka M., Yoshikawa T., Akanuma M., Kondo Y., Kang Y. J., Kishikawa T., Kato N., Xie Z., Zhang W. J., Yoshida H., Omata M., Nepveu A., Koike K., MicroRNA122 is a key regulator of α -fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. Nature Communications 2011 2 article 338 2-s2.0-79958277000 10.1038/ncomms1345
50. Coulouarn C., Factor V. M., Andersen J. B., Durkin M. E., Thorgeirsson S. S., Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009 28 40 3526 3536 2-s2.0-70349976819 10.1038/onc.2009.211
51. Tsai W.-C., Hsu P. W.-C., Lai T.-C., Chau G.-Y., Lin C.-W., Chen C.-M., Lin C.-D., Liao Y.-L., Wang J.-L., Chau Y.-P., Hsu M.-T., Hsiao M., Huang H.-D., Tsou A.-P., MicroRNA-122, a tumor suppressor MicroRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 2009 49 5 1571 1582 2-s2.0-66149114383 10.1002/hep.22806
52. Lee J., Padhye A., Sharma A., Song G., Miao J., Mo Y.-Y., Wang L., Kemper J. K., A pathway involving farnesoid X receptor and small heterodimer partner positively regulates hepatic sirtuin 1 levels via microRNA-34a inhibition. The Journal of Biological Chemistry 2010 285 17 12604 12611 2-s2.0-77951210885 10.1074/jbc.M109.094524
53. Min H.-K., Kapoor A., Fuchs M., Mirshahi F., Zhou H., Maher J., Kellum J., Warnick R., Contos M. J., Sanyal A. J., Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metabolism 2012 15 5 665 674 2-s2.0-84860469242 10.1016/j.cmet.2012.04.004
54. Castro R. E., Ferreira D. M., Afonso M. B., Borralho P. M., Machado M. V., Cortez-Pinto H., Rodrigues C. M., MiR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in rat liver and activated by disease severity in human non-alcoholic fatty liver disease. Journal of Hepatology 2013 58 1 119 125 10.1016/j.jhep.2012.08.008
55. Pogribny I. P., Starlard-Davenport A., Tryndyak V. P., Han T., Ross S. A., Rusyn I., Beland F. A., Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Laboratory Investigation 2010 90 10 1437 1446 2-s2.0-77957259450 10.1038/labinvest.2010.113
56. Budhu A., Jia H.-L., Forgues M., Liu C.-G., Goldstein D., Lam A., Zanetti K. A., Ye Q.-H., Qin L.-X., Croce C. M., Tang Z.-Y., Xin W. W., Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008 47 3 897 907 2-s2.0-40949087185 10.1002/hep.22160 (Pubitemid 351449681)
57. Hermeking H., The miR-34 family in cancer and apoptosis. Cell Death and Differentiation 2010 17 2 193 199 2-s2.0-74249123570 10.1038/cdd.2009.56
58. Raver-Shapira N., Marciano E., Meiri E., Spector Y., Rosenfeld N., Moskovits N., Bentwich Z., Oren M., Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Molecular Cell 2007 26 5 731 743 2-s2.0-34249822779 10.1016/j.molcel.2007.05.017 (Pubitemid 46856247)
59. Goldstein I., Rotter V., Regulation of lipid metabolism by p53-fighting two villains with one sword. Trends in Endocrinology and Metabolism 2012 23 11 567 575 10.1016/j.tem.2012.06.007
60. Derdak Z., Villegas K. A., Harb R., Wu A. M., Sousa A., Wands J. R., Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. Journal of Hepatology 2013 58 4 785 791 10.1016/j.jhep.2012.11.042
61. Tomita K., Teratani T., Suzuki T., p53/p66Shc-mediated signaling contributes to the progression of non-alcoholic steatohepatitis in humans and mice. Journal of Hepatology 2012 57 4 837 843 10.1016/j.jhep.2012.05.013
62. Kim N. H., Kim H. S., Li X.-Y., Lee I., Choi H.-S., Kang S. E., Cha S. Y., Ryu J. K., Yoon D., Fearon E. R., Rowe R. G., Lee S., Maher C. A., Weiss S. J., Yook J. I., A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. The Journal of Cell Biology 2011 195 3 417 433 2-s2.0-84855729906
63. Zeisberg M., Yang C., Martino M., Duncan M. B., Rieder F., Tanjore H., Kalluri R., Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. The Journal of Biological Chemistry 2007 282 32 23337 23347 2-s2.0-34548145815 10.1074/jbc.M700194200 (Pubitemid 47311952)
64. Nitta T., Kim J.-S., Mohuczy D., Behrns K. E., Murine cirrhosis induces hepatocyte epithelial mesenchymal transition and alterations in survival signaling pathways. Hepatology 2008 48 3 909 919 2-s2.0-51349133312 10.1002/hep.22397
65. Lu M., Zhang Q., Deng M., Miao J., Guo Y., Gao W., Cui Q., An analysis of human microRNA and disease associations. PLoS ONE 2008 3 10 2-s2.0-54849408182 10.1371/journal.pone.0003420 e3420
66. Guo C.-J., Pan Q., Li D.-G., Sun H., Liu B.-W., MiR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell: an essential role for apoptosis. Journal of Hepatology 2009 50 4 766 778 2-s2.0-61849096150 10.1016/j.jhep.2008.11.025
67. Rayner K. J., Esau C. C., Hussain F. N., McDaniel A. L., Marshall S. M., van Gils J. M., Ray T. D., Sheedy F. J., Goedeke L., Liu X., Khatsenko O. G., Kaimal V., Lees C. J., Fernandez-Hernando C., Fisher E. A., Temel R. E., Moore K. J., Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011 478 7369 404 407 2-s2.0-80054971110 10.1038/nature10486
68. Dávalos A., Goedeke L., Smibert P., Ramírez C. M., Warrier N. P., Andreo U., Cirera-Salinas D., Rayner K., Suresh U., Pastor-Pareja J. C., Esplugues E., Fisher E. A., Penalva L. O. F., Moore K. J., Suárez Y., Lai E. C., Fernández-Hernando C., MiR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proceedings of the National Academy of Sciences of the United States of America 2011 108 22 9232 9237 2-s2.0-79959326172 10.1073/pnas.1102281108
69. Cirera-Salinas D., Pauta M., Allen R. M., Salerno A. G., Ramírez C. M., Chamorro-Jorganes A., Wanschel A. C., Lasunción M. A., Morales-Ruiz M., Suárez Y., Baldán Á., Esplugues E., Fernández-Hernando C., Mir-33 regulates cell proliferation and cell cycle progression. Cell Cycle 2012 11 5 922 933 2-s2.0-84857953621 10.4161/cc.11.5.19421
70. Ji J., Wang X. W., New kids on the block: diagnostic and prognostic microRNAs in hepatocellular carcinoma. Cancer Biology & Therapy 2009 8 18 1686 1693 2-s2.0-77449124887
71. Alisi A., da Sacco L., Bruscalupi G., Piemonte F., Panera N., de Vito R., Leoni S., Bottazzo G. F., Masotti A., Nobili V., Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. Laboratory Investigation 2011 91 2 283 293 2-s2.0-79551592245 10.1038/labinvest.2010.166
72. Murakami Y., Toyoda H., Tanaka M., Kuroda M., Harada Y., Matsuda F., Tajima A., Kosaka N., Ochiya T., Shimotohno K., The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS ONE 2011 6 1 2-s2.0-79551541594 10.1371/journal.pone.0016081 e16081
73. Hung C. S., Liu H. H., Liu J. J., MicroRNA-200a and -200b mediated hepatocellular carcinoma cell migration through the epithelial to mesenchymal transition markers. Annals of Surgical Oncology 2013 20 3, supplement 360 368 10.1245/s10434-012-2482-4
74. Zhang L., Yang F., Yuan J. H., Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma. Carcinogenesis 2013 34 3 577 586 10.1093/carcin/bgs381
75. Li D., Liu X., Lin L., Hou J., Li N., Wang C., Wang P., Zhang Q., Zhang P., Zhou W., Wang Z., Ding G., Zhuang S.-M., Zheng L., Tao W., Cao X., MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. The Journal of Biological Chemistry 2011 286 42 36677 36685 2-s2.0-80054694898 10.1074/jbc.M111.270561
76. Klöting N., Berthold S., Kovacs P., Schön M. R., Fasshauer M., Ruschke K., Stumvoll M., Blüher M., MicroRNA expression in human omental and subcutaneous adipose tissue. PLoS ONE 2009 4 3 2-s2.0-62249144948 10.1371/journal.pone.0004699 e4699
77. Ahn J., Lee H., Jung C. H., Ha T., Lycopene inhibits hepatic steatosis via microRNA-21-induced downregulation of fatty acid-binding protein 7 in mice fed a high-fat diet. Molecular Nutrition & Food Research 2012 56 11 1665 1674 10.1002/mnfr.201200182
78. Schramedei K., Mörbt N., Pfeifer G., Läuter J., Rosolowski M., Tomm J. M., von Bergen M., Horn F., Brocke-Heidrich K., MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4. Oncogene 2011 30 26 2975 2985 2-s2.0-79959843370 10.1038/onc.2011.15
79. Vinciguerra M., Veyrat-Durebex C., Moukil M. A., Rubbia-Brandt L., Rohner-Jeanrenaud F., Foti M., PTEN down-regulation by unsaturated fatty acids triggers hepatic steatosis via an NF- Bp65/mTOR-dependent mechanism. Gastroenterology 2008 134 1 268 280 2-s2.0-37349083834 10.1053/j.gastro.2007.10. 010 (Pubitemid 350309315)
80. Vinciguerra M., Carrozzino F., Peyrou M., Carlone S., Montesano R., Benelli R., Foti M., Unsaturated fatty acids promote hepatoma proliferation and progression through downregulation of the tumor suppressor PTEN. Journal of Hepatology 2009 50 6 1132 1141 2-s2.0-67349210047 10.1016/j.jhep.2009.01.027
81. Vinciguerra M., Sgroi A., Veyrat-Durebex C., Rubbia-Brandt L., Buhler L. H., Foti M., Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog(PTEN) via microRNA-21 up-regulation in hepatocytes. Hepatology 2009 49 4 1176 1184 2-s2.0-65449119905 10.1002/hep.22737
82. Zhang Z., Zha Y., Hu W., The auto-regulatory feedback loop of microRNA-21/Programmed cell death protein 4/Activation Protein-1 (miR-21/PDCD4/AP-1) as a driving force for hepatic fibrosis development. The Journal of Biological Chemistry 2013 288 37082 37093 10.1074/jbc.M113.517953
83. Garzon R., Marcucci G., Croce C. M., Targeting microRNAs in cancer: rationale, strategies and challenges. Nature Reviews Drug Discovery 2010 9 10 775 789 2-s2.0-77957361864 10.1038/nrd3179
84. Bihrer V., Waidmann O., Friedrich-Rust M., Forestier N., Susser S., Haupenthal J., Welker M., Shi Y., Peveling-Oberhag J., Polta A., von Wagner M., Radeke H. H., Sarrazin C., Trojan J., Zeuzem S., Kronenberger B., Piiper A., Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS ONE 2011 6 10 2-s2.0-80055103381 10.1371/journal.pone.0026971 e26971
85. Karakatsanis A., Papaconstantinou I., Gazouli M., Lyberopoulou A., Polymeneas G., Voros D., Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Molecular Carcinogenesis 2013 52 4 297 303 2-s2.0-84455195714 10.1002/mc.21864
86. Roderburg C., Urban G.-W., Bettermann K., Vucur M., Zimmermann H., Schmidt S., Janssen J., Koppe C., Knolle P., Castoldi M., Tacke F., Trautwein C., Luedde T., Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 2011 53 1 209 218 2-s2.0-78751476297 10.1002/hep.23922
87. Ogawa T., Enomoto M., Fujii H., Sekiya Y., Yoshizato K., Ikeda K., Kawada N., MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut 2012 61 11 1600 1609 2-s2.0-84856012450 10.1136/gutjnl-2011-300717
88. Wang B., Majumder S., Nuovo G., Kutay H., Volinia S., Patel T., Schmittgen T. D., Croce C., Ghoshal K., Jacob S. T., Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology 2009 50 4 1152 1161 2-s2.0-70350054798 10.1002/hep.23100
89. Callegari E., Elamin B. K., Giannone F., Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology 2012 56 3 1025 1033
90. Fornari F., Gramantieri L., Ferracin M., Veronese A., Sabbioni S., Calin G. A., Grazi G. L., Giovannini C., Croce C. M., Bolondi L., Negrini M., MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008 27 43 5651 5661 2-s2.0-52949127316 10.1038/onc.2008.178
91. Li J., Wang Y., Yu W., Chen J., Luo J., Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochemical and Biophysical Research Communications 2011 406 1 70 73 2-s2.0-79952193037 10.1016/j.bbrc.2011.01.111
92. Xie Q., Chen X., Lu F., Zhang T., Hao M., Wang Y., Zhao J., McCrae M. A., Zhuang H., Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sex-determining region Y box 6 in hepatocellular carcinoma. Cancer 2012 118 9 2431 2442 2-s2.0-84857981395 10.1002/cncr.26566
93. Wang B., Li W., Guo K., Xiao Y., Wang Y., Fan J., MiR-181b promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. Biochemical and Biophysical Research Communications 2012 421 1 4 8 2-s2.0-84860329438 10.1016/j.bbrc.2012.03.025
94. Ji J., Yamashita T., Budhu A., Forgues M., Jia H.-L., Li C., Deng C., Wauthier E., Reid L. M., Ye Q.-H., Qin L.-X., Yang W., Wang H.-Y., Tang Z.-Y., Croce C. M., Wang X. W., Identification of MicroRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 2009 50 2 472 480 2-s2.0-68949170622 10.1002/hep.22989
95. Ji J., Yamashita T., Wang X. W., Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma. Cell & Bioscience 2011 1 1, article 4 2-s2.0-79960205154 10.1186/2045-3701-1-4
96. Fatima S., Lee N. P., Luk J. M., Dickkopfs and Wnt/ β -catenin signalling in liver cancer. World Journal of Clinical Oncology 2011 2 8 311 325 10.5306/wjco.v2.i8.311
97. Meng F., Glaser S. S., Francis H., Demorrow S., Han Y., Passarini J. D., Stokes A., Cleary J. P., Liu X., Venter J., Kumar P., Priester S., Hubble L., Staloch D., Sharma J., Liu C.-G., Alpini G., Functional analysis of microRNAs in human hepatocellular cancer stem cells. Journal of Cellular and Molecular Medicine 2012 16 1 160 173 2-s2.0-84855176010 10.1111/j.1582-4934.2011.01282.x
98. Zheng L., Lv G.-C., Sheng J., Yang Y.-D., Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR- α expression, a novel mechanism for the pathogenesis of NAFLD. Journal of Gastroenterology and Hepatology 2010 25 1 156 163 2-s2.0-73449136157 10.1111/j.1440-1746.2009.05949.x
99. Li Q.-J., Zhou L., Yang F., Wang G.-X., Zheng H., Wang D.-S., He Y., Dou K.-F., MicroRNA-10b promotes migration and invasion through CADM1 in human hepatocellular carcinoma cells. Tumor Biology 2012 33 5 1455 1465 2-s2.0-84859712162 10.1007/s13277-012-0396-1
100. Biagioni F., Bossel Ben-Moshe N., Fontemaggi G., MiR-10 b* a master inhibitor of the cell cycle, is down-regulated in human breast tumours. EMBO Molecular Medicine 2012 4 11 1214 1229 10.1002/emmm.201201483
101. Biagioni F., Bossel Ben-Moshe N., Fontemaggi G., Yarden Y., Domany E., Blandino G., The locus of microRNA-10b: a critical target for breast cancer insurgence and dissemination. Cell Cycle 2013 12 15 2371 2375 10.4161/cc.25380
102. Jin X., Chen Y.-P., Kong M., Zheng L., Yang Y.-D., Li Y.-M., Transition from hepatic steatosis to steatohepatitis: unique microRNA patterns and potential downstream functions and pathways. Journal of Gastroenterology and Hepatology 2012 27 2 331 340 2-s2.0-84856198739 10.1111/j.1440-1746.2011.06864.x
103. Lan F.-F., Wang H., Chen Y.-C., Chan C.-Y., Ng S. S., Li K., Xie D., He M.-L., Lin M. C., Kung H.-F., Hsa-let-7g inhibits proliferation of hepatocellular carcinoma cells by downregulation of c-Myc and upregulation of p16INK4A. International Journal of Cancer 2011 128 2 319 331 2-s2.0-78649561463 10.1002/ijc.25336
104. Hou W., Tian Q., Steuerwald N. M., Schrum L. W., Bonkovsky H. L., The let-7 microRNA enhances heme oxygenase-1 by suppressing Bach1 and attenuates oxidant injury in human hepatocytes. Biochimica et Biophysica Acta 2012 1819 11-12 1113 1122 10.1016/j.bbagrm.2012.06.001
105. Zhu X.-M., Wu L.-J., Xu J., Yang R., Wu F.-S., Let-7c microRNA expression and clinical significance in hepatocellular carcinoma. The Journal of International Medical Research 2011 39 6 2323 2329 2-s2.0-84555170184 10.1177/147323001103900631
106. Hou J., Lin L., Zhou W., Wang Z., Ding G., Dong Q., Qin L., Wu X., Zheng Y., Yang Y., Tian W., Zhang Q., Wang C., Zhang Q., Zhuang S.-M., Zheng L., Liang A., Tao W., Cao X., Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011 19 2 232 243 2-s2.0-79751484450 10.1016/j.ccr.2011.01.001
107. Adlakha Y. K., Saini N., MicroRNA-128 downregulates Bax and induces apoptosis in human embryonic kidney cells. Cellular and Molecular Life Sciences 2011 68 8 1415 1428 2-s2.0-79953712904 10.1007/s00018-010-0528-y
108. Adlakha Y. K., Saini N., MiR-128 exerts pro-apoptotic effect in a p53 transcription-dependent and -independent manner via PUMA-Bak axis. Cell Death and Disease 2013 4 e542 10.1038/cddis.2013.46
109. Adlakha Y. K., Khanna S., Singh R., Singh V. P., Agrawal A., Saini N., Pro-apoptotic miRNA-128-2 modulates ABCA1, ABCG1 and RXR α expression and cholesterol homeostasis. Cell Death and Disease 2013 4 e780 10.1038/cddis.2013. 301
110. Lu J., Getz G., Miska E. A., Alvarez-Saavedra E., Lamb J., Peck D., Sweet-Cordero A., Ebert B. L., Mak R. H., Ferrando A. A., Downing J. R., Jacks T., Horvitz H. R., Golub T. R., MicroRNA expression profiles classify human cancers. Nature 2005 435 7043 834 838 2-s2.0-20444460289 10.1038/nature03702 (Pubitemid 40839735)
111. Li J., Smyth P., Flavin R., Cahill S., Denning K., Aherne S., Guenther S. M., O'Leary J. J., Sheils O., Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnology 2007 7, article 36 2-s2.0-34447506198 10.1186/1472-6750-7-36 (Pubitemid 47065165)
112. Callari M., Tiberio P., de Cecco L., Feasibility of circulating miRNA microarray analysis from archival plasma samples. Analytical Biochemistry 2013 437 2 123 125 10.1016/j.ab.2013.03.002
113. Blum H. E., Hepatocellular carcinoma: therapy and prevention. World Journal of Gastroenterology 2005 11 47 7391 7400 2-s2.0-31144437639 (Pubitemid 43126017)
114. Tanaka S., Arii S., Molecularly targeted therapy for hepatocellular carcinoma. Cancer Science 2009 100 1 1 8 2-s2.0-58149299317 10.1111/j.1349-7006. 2008.01006.x
115. Llovet J. M., Bruix J., Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008 48 4 1312 1327 2-s2.0-54449083925 10.1002/hep.22506
116. Barbato C., Arisi I., Frizzo M. E., Brandi R., da Sacco L., Masotti A., Computational challenges in miRNA target predictions: to be or not to be a true target? Journal of Biomedicine and Biotechnology 2009 2009 9 2-s2.0-68149171901 10.1155/2009/803069 803069
117. Calvert V. S., Collantes R., Elariny H., Afendy A., Baranova A., Mendoza M., Goodman Z., Liotta L. A., Petricoin E. F., Younossi Z. M., A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology 2007 46 1 166 172 2-s2.0-34547488563 10.1002/hep.21688 (Pubitemid 47171933)
118. Sookoian S., Pirola C. J., Systems biology elucidates common pathogenic mechanisms between nonalcoholic and alcoholic-fatty liver disease. PLoS ONE 2013 8 3 e58895 10.1371/journal.pone.0058895
119. Moylan C. A., Pang H., Dellinger A., Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. Hepatology 2013 59 2 471 482 10.1002/hep.26661
120. Kota J., Chivukula R. R., O'Donnell K. A., Wentzel E. A., Montgomery C. L., Hwang H.-W., Chang T.-C., Vivekanandan P., Torbenson M., Clark K. R., Mendell J. R., Mendell J. T., Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009 137 6 1005 1017 2-s2.0-66449136951 10.1016/j.cell.2009.04.021
121. Huang X., Schwind S., Yu B., Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clinical Cancer Research 2013 19 9 2355 2367
122. Park J.-K., Kogure T., Nuovo G. J., Jiang J., He L., Kim J. H., Phelps M. A., Papenfuss T. L., Croce C. M., Patel T., Schmittgen T. D., MiR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Research 2011 71 24 7608 7616 2-s2.0-84255192032 10.1158/0008-5472.CAN-11-1144
123. Moore K. J., Rayner K. J., Suárez Y., Fernández-Hernando C., MicroRNAs and cholesterol metabolism. Trends in Endocrinology and Metabolism 2010 21 12 699 706 2-s2.0-78650262887 10.1016/j.tem.2010.08.008
124. Kukreja R. C., Yin C., Salloum F. N., MicroRNAs: new players in cardiac injury and protection. Molecular Pharmacology 2011 80 4 558 564 2-s2.0-80053205337 10.1124/mol.111.073528
125. Sato F., Tsuchiya S., Meltzer S. J., Shimizu K., MicroRNAs and epigenetics. The FEBS Journal 2011 278 10 1598 1609 2-s2.0-79955581917 10.1111/j.1742-4658.2011.08089.x
126. Pirola C. J., Gianotti T. F., Castano G. O., Sookoian S., Circulating microRNA-122 signature in nonalcoholic fatty liver disease and cardiovascular
127. Kim V. N., Nam J.-W., Genomics of microRNA. Trends in Genetics 2006 22 3 165 173 2-s2.0-33344477448 10.1016/j.tig.2006.01.003 (Pubitemid 43290020)